Signal
FDA approves Corcept’s first-in-class ovarian cancer drug Lifyorli
Evidence first: scan the strongest sources, then decide whether to go deeper.
rss
clinical_trialsfdaapprovalsdrug_development
Source links limited
You can inspect the signal and top sources here. Full source links and workflow tools unlock on the flagship sample or in the app.
Evidence preview
- Fierce Pharmafiercepharma.com
- pharmaphorumpharmaphorum.com
Overview
Corcept Therapeutics has received FDA approval for Lifyorli (relacorilant), a first-in-class drug targeting adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The approval applies to patients who have had one to three prior systemic treatments, with at least one including bevacizumab. This milestone represents a significant advancement in ovarian cancer treatment, providing a novel therapeutic option for patients with limited alternatives.
Entities
Corcept Therapeutics
Score total
0.98
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- FDA approval follows recent clinical trials demonstrating efficacy in resistant ovarian cancers.
- Addresses an unmet medical need for patients with prior bevacizumab treatment.
- Corcept’s milestone could influence future drug development in this cancer category.
Why it matters
- Lifyorli is the first FDA-approved drug in its class for platinum-resistant ovarian cancer.
- Provides a new treatment option for patients with limited alternatives after prior therapies.
- Represents progress in addressing difficult-to-treat ovarian cancer subtypes.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: medium
Recurring claims
- FDA approved Corcept’s Lifyorli for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after prior treatments including bevacizumab
How sources frame it
- News Sources: neutral
Consolidated FDA approval news for Corcept's Lifyorli with focus on clinical and regulatory significance.